InMed Pharmaceuticals Inc. - Common Shares (INM)
3.4600
-0.3300 (-8.71%)
NASDAQ · Last Trade: Jun 27th, 12:17 AM EDT
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 24, 2025
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · June 24, 2025
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · June 24, 2025
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via Chartmill · June 24, 2025
InMed stock jumped after preclinical data showed INM-901 lowered brain inflammation tied to Alzheimer's and improved cognitive function in models.
Via Benzinga · June 24, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 24, 2025
Via Benzinga · June 24, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 2, 2025

Via Benzinga · June 2, 2025

The positive trial results propelled InMed into the top 25 trending stocks on Stocktwits, with a flood of bullish comments on the platform.
Via Stocktwits · January 21, 2025

Via Benzinga · January 22, 2025

InMed Pharmaceuticals shares are trading higher by 45% during Tuesday's session. The company announced that INM-901 reduced Alzheimer 's-related inflammation in a preclinical study.
Via Benzinga · January 21, 2025

Via Benzinga · August 22, 2024

Via Benzinga · August 21, 2024

Via Benzinga · August 20, 2024

InMed Pharmaceuticals advances INM-901 as an oral treatment for Alzheimer's. Preclinical studies show the small molecule drug achieves effective brain levels, offering a promising alternative to traditional delivery methods.
Via Benzinga · August 20, 2024

The Rising Importance Of Minor Cannabinoids In The Growing Edible Market
Via News Direct · July 19, 2024

A good rating for growth in the Portfolio Grader doesn't tell the full picture. These are all growth stocks to avoid now.
Via InvestorPlace · June 28, 2024